Table 1.
Baseline patient characteristics*
| Female | Male | |||
| Placebo (N=23) |
GSK2881078 (N=24) |
Placebo (N=24) |
GSK2881078 (N=25) |
|
| Age, mean (SD), years | 64.7 (7.16) | 64.2 (7.93) | 64.0 (7.27) | 67.2 (6.08) |
| Ethnicity, n (%) | ||||
| Black or African American | 0 | 1 (4) | 2 (8) | 2 (8) |
| White/Caucasian/European | 23 (100) | 23 (96) | 22 (92) | 23 (92) |
| BMI (kg/m2), mean (SD) | 23.9 (3.93) | 24.2 (3.78) | 25.5 (4.22) | 26.0 (4.51) |
| Postbronchodilator FEV1 % predicted, mean (SD) | 46.2 (10.82) | 49.6 (9.69) | 51.2 (10.63) | 48.0 (11.80) |
*Baseline characteristics for the all randomised subjects who receive at least one dose of study medication.
BMI, body mass index; FEV1, forced expiratory volume in 1 s.;